A Study of the VISION5 Product in Patients With Glaucoma or Ocular Hypertension

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01943721

Enrollment

Registered

2013-09-17

Start date

2013-10-31

Completion date

2014-06-30

Last updated

2014-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ocular Hypertension, Primary Open Angle Glaucoma

Brief summary

The objective of this Phase 1 study is to evaluate the VISION5 Product's safety and efficacy.

Interventions

DRUGVISION5 Product

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Written informed consent * Primary open-angle glaucoma or ocular hypertension in both eyes * Best-corrected distance vision of 20/100 or better * Stable visual field

Exclusion criteria

* Cup-to-disc ratio greater than 0.8 * Laser surgery for glaucoma/ocular hypertension on one or both eyes within the last 12 months * Corneal refractive surgery within prior 6 months * Past history of any incisional surgery for glaucoma at any time * Corneal abnormalities that would interfere with tonometry readings * Current participation in an investigational drug or device study or participation in such a study within 30 days of screening

Design outcomes

Primary

Measure	Time frame
Ocular Tonometry (change from baseline)	Week 2, 6, 12 and Months 4,5,6

Secondary

Measure	Time frame
Safety as assessed by Slit Lamp Exam	Weeks 2,6,12 and Months 4,5,6

Countries

Latvia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026